Seattle biotechnology company Oncothyreon has acquired another local firm, Alpine Biosciences, for about $27 million in stock.
Alpine Biosciences, an early stage company that has not advanced any drugs into clinical trials, was formed by Mitch Gold, who stepped down as CEO of Dendreon in 2012, and Jay Venkatesan, a doctor and biotech investment manager. The company has licensed nanoparticle technology it says can “encapsulate” large drug molecules and deliver them to targeted cells for treating diseases.
The 9.3 million shares paid for Alpine represent about one eighth of the company’s currently outstanding stock. Oncothyreon, which has a market capitalization of about $216 million, said Venkatesan will join the company as an executive vice president.
Oncothyreon has several cancer drugs in clinical trials, and collaboration deals with larger biotech and pharmaceutical companies.
Most Read Business Stories
- Peek inside the Hunts Point mansion, famous for huge art collection, that sold for record $37.5 million WATCH
- Largest e-recycling fraud in U.S. history sends owners of Kent firm to prison
- How much has the 737 MAX crisis affected Boeing's finances? We're about to find out
- Boeing CEO denies any "technical slip" in 737 MAX crashes, as grounding cuts into profit and cash reserves
- San Francisco seethes over tech, housing and the homeless